Abstracts Archive - Page 1347 of 2425 - ACR Meeting Abstracts

Abstract Number: 2122 • 2017 ACR/ARHP Annual Meeting
Association of Retroperitoneal Fibrosis with Malignancy
Sang Jin Lee¹, Jung Su Eun¹, Na Ri Kim², Eon Jeong Nam¹, Yeong Wook Song³ and Young Mo Kang⁴, ¹Division of Rheumatology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea, Republic of (South), ²Internal Medicine (Rheumatology), Kyungpook National University School of Medicine, Daegu, Korea, Republic of (South), ³Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ⁴Division of Rheumatology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Republic of Korea, Daegu, Korea, Republic of (South)
Background/Purpose: Retroperitoneal fibrosis (RPF) is a periaortic sclerotic disease that encases adjacent structures, particularly the ureters. Because it is unclear whether RPF is associated with…
Abstract Number: 2123 • 2017 ACR/ARHP Annual Meeting
Protein-Losing Enteropathy in Patients with Systemic Autoimmune Diseases: Characterization of 263 Cases (GEAS-SEMI Spanish Cohort)
Alejandra Flores-Chavez^1,2,3, Soledad Retamozo^4,5,6, Angel Robles⁷, Guadalupe Fraile Rodriguez⁸, Sofia Arteaga^9,10, Celeste Galceran-Chaves¹¹, Roberto Pérez-Alvarez¹², Marta Pérez de Lis¹², Belchin Kostov¹³, Manuel Ramos-Casals^14,15 and Pilar Brito-Zerón^14,16, ¹Department of Autoimmune Diseases, ICMiD, Hospital Clínic Barcelona, Spain., Barcelona, Spain, ²Unidad de Investigación Biomédica 02 (Unidad de Investigación en Epidemiología Clínica), UMAE, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Jalisco, Mexico, ³Programa de Doctorado en Ciencias Médicas, Centro Universitario de Investigaciones Biomédicas (CUIB), Universidad de Colima, Colima, Mexico, Mexico, Mexico, ⁴Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Córdoba, Consejo Nacional de Investigaciones Científicas y Técnicas (INICSA-UNC-CONICET), Cordoba, Argentina, ⁵Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Barcelona, Spain, ⁶Rheumatology Unit, Hospital Privado Universitario de Córdoba, Institute University of Biomedical Sciences University of Córdoba (IUCBC), Cordoba, Argentina, ⁷Department of Internal Medicine, Hospital La Paz, Madrid, Madrid, Spain, ⁸Internal Medicine, Hospital Ramón y Cajal, Madrid, Madrid, Spain, ⁹Department of Autoimmune Diseases, ICMiD, Hospital Clínic Barcelona, Barcelona, Spain, ¹⁰Universidad de Antioquía, Medellín, Colombia, Medellin, Colombia, ¹¹Neuroscience Clinical Institute, Hospital Clínic, Barcelona, Barcelona, Spain, ¹²Department of Internal Medicine, Hospital Alvaro Cunqueiro, Vigo, Vigo, Spain, ¹³Primary Care Research Group, IDIBAPS, Centre d’Assistència Primària ABS Les Corts, CAPSE, Barcelona, Barcelona, Spain, ¹⁴Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ¹⁵Department of Medicine, University of Barcelona, Barcelona, Spain., Barcelona, Spain, ¹⁶Autoimmune Diseases Unit, Department of Medicine, Hospital CIMA- Sanitas, Barcelona., Bacelona, Spain
Background/Purpose: Protein-losing enteropathy (PLE) is a rare condition characterized by a loss of serum protein into the gastrointestinal tract resulting in hypoproteinemia, which can be…
Abstract Number: 2124 • 2017 ACR/ARHP Annual Meeting
Mixed Connective Tissue Disorder Has Higher Prevalence of Arthritis and Use of Methotrexate Than Systemic Lupus Erythematosus
Gunasekaran Sambandam^1,2, Dr. Varun Dhir³, Dr. Mahesh Prakash⁴, Ranjana Minz⁵, Shefali Sharma⁶ and Aman Sharma⁷, ¹Internal Medicine, Post Graduate Institute of Medical Education and Research (PGIMER), chandigarh, India, ²Internal medicine, Post graduate Institute of medical education and research, chandigarh, India, ³Internal Medicine ( Clinical Rheumatology), Post Graduate Institute of Medical Education and Research, chandigarh, India, ⁴Radio Diagnosis, Post Graduate Institute of Medical Education and Research, chandigarh, India, ⁵Department of Immunopathology,, PGIMER,, Chandigarh, India, ⁶Department of Medicine, All India Institute of Medical Sciences, New Delhi, New Delhi, India, ⁷Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose: Mixed connective disease is a multi-system disorder with overlapping features of SLE, rheumatoid arthritis, scleroderma and polymyositis/dermatomyositis with high titres of U1 RNP. Arthritis…
Abstract Number: 2125 • 2017 ACR/ARHP Annual Meeting
Identification of Long-Term Prognostic Factors for Relapse or Exacerbation in Patients with Pulmonary Sarcoidosis: A Single Center Long-Term Observational Cohort Study
Okinori Murata¹, Atsuko Kudo² and Katsuya Suzuki³, ¹Department of Pulmonary medicine, Hachinohe Red Cross Hospital, Hachinohe, Japan, ²Hachinohe Red Cross Hospital, Hachinohe, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medcine, Tokyo, Japan
Background/Purpose: Sarcoidosis is a systemic granulomatous disease that can affect multiple organs, and in particular lung involvements are common and found in more than 90%…
Abstract Number: 2126 • 2017 ACR/ARHP Annual Meeting
Safety of Immune Checkpoint Inhibitors for the Treatment of Melanoma, Bronchopulmonary and Urologic Neoplasms in Patients with Preexisting Autoimmune Disease
Alice Tison¹, Gilles Quere¹, Laurent Misery¹, Thierry Lesimple², Marie Marcq³, Stephanie Martinez⁴, Florence Brunet-Possenti⁵, Sandrine Mansard⁶, Nathalie Beneton⁷, Mickaël Lambert⁸, Christophe Roge⁸, Ouidad Zehou⁹, Francois Aubin¹⁰, Sarah Maanaoui¹¹, Camille Scalbert¹¹, damien giacchero¹², Nora Kramkimel¹³, François Skowron¹⁴, Anne Pham-Ledard¹⁵, Divi Cornec¹ and Marie Kostine¹⁵, ¹CHU Brest, Brest, France, ²Centre Eugène Marquis, Rennes, France, ³CH Vendee, La Roche-sur-Yon, France, ⁴CH Aix-en-Provence, Aix-en-Provence, France, ⁵CHU Bichat, Paris, France, ⁶CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁷CH Le Mans, Le Mans, France, ⁸CH Morlaix, Morlaix, France, ⁹Hôpital Henri Mondor, Creteil, France, ¹⁰CHU Besancon, Besancon, France, ¹¹CHU Lille, Lille, France, ¹²Centre Antoine Lacassagne, Nice, France, ¹³CHU Cochin, Paris, France, ¹⁴CH Valence, Valence, France, ¹⁵CHU Bordeaux, Bordeaux, France
Background/Purpose: Immune checkpoint inhibitors (ICIs), by inhibiting immunosuppressive molecules overexpressed in the tumoral environment such as CTLA-4 or PD1, increase the anti-tumor immune response and…
Abstract Number: 2127 • 2017 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Inhibitors for Sarcoidosis
Stefanie Wade¹ and Mollie Carruthers², ¹Medicine, University of Connecticut Health Center, Farmington, CT, ²Rheumatology, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Patients with sarcoidosis refractory to standard treatment are a therapeutic challenge and are often managed by a variety of specialists due to the heterogeneity…
Abstract Number: 2128 • 2017 ACR/ARHP Annual Meeting
A Systematic Review of the Management of Patients with Preexisting Rheumatologic Diseases Receiving Checkpoint Inhibitors for Cancer
Noha Abdel-Wahab^1,2, Mohsin Shah¹, Maria A. Lopez-Olivo¹ and Maria Suarez-Almazor¹, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ²Rheumatology and Rehabilitation Department, Assiut University Hospitals, Assiut, Egypt, Assiut, Egypt
Background/Purpose: The incidence and management of rheumatologic immune-related adverse events (irAEs) as a consequence of the checkpoint inhibitor (CPI) therapy in patients with cancer has…
Abstract Number: 2129 • 2017 ACR/ARHP Annual Meeting
Evaluation of Suppurative Hidradenitis in Patients with Chronic Arthritis Treated with Full and Tapered Biological Disease-Modifying Antirheumatic Drugs
Larissa Valor¹, Diana Hernández-Flórez², Tamara del Río², Juan Gabriel Ovalles-Bonilla³, Julia Martínez-Barrio⁴, Iustina Janta¹, Belen Serrano⁵, Juan Carlos Nieto¹, María Correyero¹, Leticia Garcia Montoya⁶, Carlos M Gonzalez¹, Indalecio Monteagudo¹ and Francisco Javier López Longo⁷, ¹Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Rheumatology, Gregorio Marañón University General Hospital, Madrid, Spain, ³Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain, ⁴Servicio de Reumatologia, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁵Rheumatology, Hospital General Universitario Gregorio Marañón, Genoa, Italy, ⁶Gregorio Marañón University General Hospital, Madrid, Spain, ⁷Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
Background/Purpose: Suppurative Hidradenitis (SH) is an inflammatory skin disease with often disappointing response to treatment. It is a disorder of apocrine glands (axillary, inguinal and…
Abstract Number: 2130 • 2017 ACR/ARHP Annual Meeting
Joint Manifestations in Patients Diagnosed with Idiopathic Inflammatory Myopathy: Multicenter Registry on Inflammatory Myositis from the Rheumatology Society in Madrid, Spain
Larissa Valor¹, Diana Hernández-Flórez², Julia Martínez-Barrio³, Beatriz E. Joven⁴, Laura Nuño⁵, Carmen Larena⁶, Irene Llorente⁷, Carmen Barbadillo⁸, Paloma Garcia De La Peña⁹, Lucía Ruíz Gutiérrez¹⁰, Henry Moruno Cruz¹¹, Tatiana Cobo-Ibáñez¹², Raquel Almodóvar González¹³, Leticia Lojo¹⁴, MARIA JESUS GARCIA DE YEBENES Y PROUS¹⁵ and Francisco Javier López Longo¹⁶, ¹Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Rheumatology, Gregorio Marañón University General Hospital, Madrid, Spain, ³Servicio de Reumatologia, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁴Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁵Servicio de Reumatologia, Hospital Universitario La Paz, Madrid, Spain, ⁶Hospital Gregorio Marañón, Madrid, Spain, ⁷Rheumatology, H.U. La Princesa, Madrid, Spain, ⁸Hospital Universitario Puerta de Hierro, Madrid, Spain, ⁹Rheumatology, Hospital Madrid Norte Sanchinarro, Madrid, Spain, ¹⁰Pediatric Rheumathology Unit, University Children's Hospital Niño Jesús, Madrid, Spain, ¹¹University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology department, Alcalá de Henares, Madrid, Spain, ¹²Hospital Universitario Reina Sofía, Universidad Europea de Madrid, Madrid, Spain, ¹³Rheumatology Unit, Hospital Universitario Fundación Alcorcón, Madrid, Spain, ¹⁴Rheumatology, Hospital Universitario La Paz, Spain, Spain, ¹⁵Institute for Musculoskeletal Health, Madrid, Spain, ¹⁶Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
Background/Purpose: Idiopathic inflammatory myopathies (IIM) comprise a heterogeneous group of autoimmune conditions characterized by muscle non-suppurative inflammation, progressive muscle weakness and a variety of extra-muscular…
Abstract Number: 2131 • 2017 ACR/ARHP Annual Meeting
Longitudinal Cohort Study of Anti-PM/Scl Myositis Patients: Mild Muscle and Lung Involvement with Prominent Perivascular Inflammation
Rebecca De Lorenzo¹, Iago Pinal-Fernandez², Maria Casal-Dominguez², Wilson Huang², Jose Cesar Milisenda¹, Cassie Parks², Katherine Pak³, Cheilonda Johnson⁴, Eleni Tiniakou⁵, Jemima Albayda⁶, Julie J. Paik⁶, Sonye K. Danoff⁷, Lisa Christopher-Stine⁷, Andrea Corse⁸ and Andrew Mammen^3,9, ¹Muscle Disease Unit, NIAMS, NIH, Bethesda, MD, ²NIAMS, NIH, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴Medicine/Pulmonology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Neurology, Johns Hopkins University, Baltimore, MD, ⁹Neurology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: To describe the clinical and serologic features, as well as the disease course and response to therapy of anti-PM/Scl patients. Methods: All Johns Hopkins…
Abstract Number: 2132 • 2017 ACR/ARHP Annual Meeting
Angiogenesis and VEGF-Expressing Cells Are Identified Predominantly in the Fascia Rather Than the Muscle in the Early Phase of Dermatomyositis
Ken Yoshida^1,2, Haruyasu Ito¹, Kazuhiro Furuya¹, Taro Ukichi¹, Kentaro Noda¹ and Daitaro Kurosaka¹, ¹Division of Rheumatology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan, ²Internal Medicine, Jikei University School of Medicine, Tokyo, Japan
Background/Purpose: We previously showed that fasciitis is a frequent manifestation of the disease in dermatomyositis (DM) but not in polymyositis (PM) and that DM-associated fasciitis…
Abstract Number: 2133 • 2017 ACR/ARHP Annual Meeting
Clinical Characteristics of the Patients with Recurrent Myositis in Polymyositis and Dermatomyositis: A Retrospective Study
Akira Nishino, Yasuhiro Katsumata, Hidenaga Kawasumi, Yasushi Kawaguchi and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Patients with polymyositis (PM) and dermatomyositis (DM) often experience relapse–remitting courses and recurrent myositis. However, only a few studies focused on this issue, and…
Abstract Number: 2134 • 2017 ACR/ARHP Annual Meeting
Identification of Multiple Cancer Associated Myositis Specific Antibodies in Idiopathic Inflammatory Myopathies: A Large Longitudinal Cohort Study
Hanbo Yang¹, Qinglin Peng², Liguo Yin¹, Shanshan Li¹, Jingli Shi¹, Yamei Zhang¹, Xin Lu¹, Xiaoming Shu¹, Sigong Zhang³ and Guochun Wang⁴, ¹Rheumatology, China-Japan Friendship Hospital, Beijing, China, ²Rheuamtology, China-Japan Friendship Hospital, Beijing, China, ³Rheumatology, Lanzhou University Second Hospital, Lanzhou, China, ⁴China-Japan Friendship Hospital, Beijing, China
Background/Purpose: Paraneoplastic myositis provide an exceptional opportunity for cancer triggered autoimmunity. Myositis specific antibodies (MSAs) show great clinical utility in IIM diagnosis and classification. However,…
Abstract Number: 2135 • 2017 ACR/ARHP Annual Meeting
ADAM-17 Is Expressed in the Inflammatory Myopathy, and Is Involved with Interstitial Lung Disease
Airi Nishimi, Takeo Isozaki, Shinichiro Nishimi, Sho Ishii, Takahiro Tokunaga, Hidekazu Furuya, Kuninobu Wakabayashi and Tsuyoshi Kasama, Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan
Background/Purpose: A disintegrin and metalloprotesase (ADAM) family is protease that is thought to have an important role in tissue destruction and inflammatory reaction. ADAMs are…
Abstract Number: 2136 • 2017 ACR/ARHP Annual Meeting
Association of HLA-DQA1*05 with the Presence of Interstitial Lung Disease Independent of Autoantibody Status in Caucasian Patients with Polymyositis and Dermatomyositis
Adam Schiffenbauer¹, Sara Faghihi-Kashani², Terrance P. O'Hanlon¹, Willy Flegel³, Sharon Adams³, Ira N. Targoff⁴, Chester V. Oddis^5,6, Rohit Aggarwal^7,8, Lisa G Rider¹, Steven R. Ytterberg⁹, Lisa Christopher-Stine¹⁰, Sonye K. Danoff¹¹, Paul F. Dellaripa^12,13, Ejaz Shamim¹⁴, Andrew Mammen¹⁵ and Frederick W Miller¹⁶, ¹Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ²Environmental Autoimmunity Group, National Institute of Environmental Health, Bethesda, MD, ³Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, ⁴VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Rheumatology/Clinical Immunology, Unviersity of Pittsburgh/University of Pittsburgh Medical Center, Pittsburgh, PA, ⁶Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Pediatria II, Reumatologia, PRINTO, Istituto Giannina Gaslini, Genoa, Italy, ⁸Department of Medicine / Rheumtology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁹Rheumatology, Mayo Clinic, Rochester, MN, ¹⁰Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ¹¹Medicine/Pulmonary, Johns Hopkins University, Baltimore, MD, ¹²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ¹³Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, ¹⁴9. Department of Neurology, Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, MD, ¹⁵Muscle Diseases Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases. National Institutes of Health, Bethesda, MD, ¹⁶Clinical Research Branch / Environmental Autoimmunity Group, NIH, Bethesda, MD
Background/Purpose: Interstitial lung disease (ILD) is a frequent complication and a major contributor to mortality and morbidity in polymyositis and dermatomyositis (PM/DM). Prior studies have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].